NAVB - Navidea Biopharmaceuticals, Inc

NYSE American - NYSE American Delayed Price. Currency in USD
0.1700
+0.0197 (+13.11%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.1503
Open0.1550
Bid0.00 x 1100
Ask0.00 x 1000
Day's Range0.1550 - 0.1780
52 Week Range0.1000 - 0.4200
Volume283,012
Avg. Volume627,731
Market Cap30.904M
Beta (3Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)-0.10
Earnings DateMar 24, 2017 - Mar 27, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.25
Trade prices are not sourced from all markets
  • Business Wire21 days ago

    Navidea Biopharmaceuticals Announces Extension of NYSE American Listing

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the receipt of a notice from the NYSE American LLC (the “NYSE American”) on January 28, 2019 that the NYSE American has granted the Company an extension until March 31, 2019 to regain compliance with Section 1003(f)(v) of the NYSE American’s continued listing standards. Navidea previously disclosed that it received a notification from the NYSE American stating that Navidea was not in compliance with certain provisions of the NYSE American continued listing standards, including Section 1003(f)(v), which relates to the selling price per share of the Company’s securities.

  • Business Wire29 days ago

    Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Ohio Supreme Court has dismissed a Petition filed by Capital Royalty Partners II, L.P. and affiliated entities. On August 27, 2018, Capital Royalty Partners II, L.P. and several affiliated entities ("CRG") filed a Petition with the Ohio Supreme Court seeking a Writ of Prohibition against the Honorable Mark A. Serrott asserting that Judge Serrott's refusal to dismiss Navidea Biopharmaceuticals, Inc.'s pending Ohio litigation against CRG was improper and that Judge Serrott lacked jurisdiction over CRG with respect to the case issues.

  • Business Wire3 months ago

    Navidea Biopharmaceuticals Announces Patent Extension for Lymphoseek®

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 23, 2018 the U.S. Food and Drug Administration (“FDA”) released a letter to the U.S. Patent and Trademark Office (“USPTO”) indicating that the USPTO is allowed to extend the patent duration of U.S. patent 6,409,990 for an additional 5 years or until May 12, 2025. This patent claims Lymphoseek® (technetium (Tc 99m) tilmanocept) and has been exclusively licensed with varying geographical and medical indication coverages to Cardinal Health and Navidea. Allowance of this patent extension will permit Cardinal Health and Navidea to extend their exclusive rights to manufacture and commercialize Lymphoseek until the end of the extended patent term in 2025.

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of NAVB earnings conference call or presentation 7-Nov-18 9:30pm GMT

    Q3 2018 Navidea Biopharmaceuticals Inc Earnings Call

  • Business Wire3 months ago

    Navidea Biopharmaceuticals Appoints Adam Cutler to Board of Directors

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Adam Cutler to the Company’s board of directors, effective December 1, 2018. “We are pleased to welcome Mr. Cutler to Navidea’s board of directors,” said Mr. Jed A. Latkin, Chief Executive Officer of Navidea.

  • Business Wire3 months ago

    Navidea Biopharmaceuticals Appoints Dr. Michael Rosol as Chief Medical Officer

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Michael Rosol, PhD as Chief Medical Officer of Navidea, effective December 17, 2018. Dr. Rosol brings to this position over 10 years of experience in biomedical imaging and commercialization.

  • Business Wire3 months ago

    Navidea Biopharmaceuticals to Present at the 11th Annual LD Micro Event 2018

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Chief Executive Officer, Jed Latkin, will present a corporate overview of the Company at the 11th Annual LD Micro Event, being held December 4-6, 2018 in Bel-Air, California. The LD Micro Event is one of the largest and most influential independent micro-cap conferences. Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.

  • Business Wire3 months ago

    Navidea Biopharmaceuticals Announces Presentation at the Radiological Society of North America (RSNA) 104th Scientific Assembly and Annual Meeting 2018

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Dr. David Ralph, Director of Drug Development and IP Manager of Navidea, will be presenting at the RSNA 104th Scientific Assembly and Annual Meeting, which is taking place November 25-30, 2018 in Chicago, IL. The oral presentation will highlight an abstract evaluated and selected through a competitive, blind peer-review process.

  • Business Wire3 months ago

    Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan to Board of Directors

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of Kathy Rouan, PhD, to the Company’s board of directors, effective December 1, 2018. “We are excited for Dr. Rouan to join Navidea’s board of directors at an instrumental time in the Company’s development,” said Mr. Jed A. Latkin, Chief Executive Officer of Navidea.

  • Associated Press4 months ago

    Navidea: 3Q Earnings Snapshot

    On a per-share basis, the Dublin, Ohio-based company said it had a loss of 2 cents. The biopharmaceutical posted revenue of $231,500 in the period. Its adjusted revenue was $231,000. In the final minutes ...

  • Business Wire4 months ago

    Navidea Biopharmaceuticals Reports Third Quarter 2018 Financial Results

    Conference Call to be held Wednesday, November 7th, 2018 at 4:30 pm ET

  • Business Wire4 months ago

    Navidea Biopharmaceuticals Schedules Third Quarter 2018 Earnings Conference Call and Business Update

    Conference call to take place November 7th, 2018, at 4:30 pm E.T.

  • Business Wire4 months ago

    Navidea Biopharmaceuticals Wins Dismissal of Platinum Litigation

    On October 31, 2018, Judge Valerie Caproni of the United States District Court for the Southern District of New York entered an Opinion and Order, as well as a Judgment, dismissing all claims raised by Platinum-Montaur Life Sciences LLC (“Platinum-Montaur”) in its litigation against Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”). Platinum’s claims arose from a note and loan agreement entered on July 25, 2012 (the “Note”), under which Navidea borrowed certain sums from Platinum-Montaur. Thereafter, Platinum-Montaur entered into an assignment with its affiliate Platinum Partners Credit Opportunities Master Fund, LP (“PPCO”) whereby Platinum-Montaur assigned its interests under the Note to PPCO.

  • Business Wire4 months ago

    Navidea Biopharmaceuticals Receives Acceptance Letter from NYSE American

    As previously disclosed, on August 14, 2018, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received a notification (the “Deficiency Letter”) from the NYSE American LLC (the “NYSE American”) stating that Navidea was not in compliance with Section 1003(a)(ii) and Section 1003(f)(v) of the NYSE American continued listing standards, which relate to stockholders’ equity and the selling price per share of the Company’s securities. As required by the NYSE American, Navidea submitted a plan to the NYSE American by September 14, 2018 advising of actions it has taken or will take to regain compliance with the continued listing standards by February 14, 2020.

  • Business Wire4 months ago

    Navidea Biopharmaceuticals to Present Data on the Manocept Platform at 2018 ACR Annual Meeting

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the company will present a poster detailing results from the Company’s clinical trials assessing Tc 99m tilmanocept in rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) 2018 Annual Meeting, being held October 19-24, 2018 in Chicago, Illinois. Tc 99m tilmanocept is the first product developed and commercialized by the Company based on the Manocept platform.

  • Business Wire5 months ago

    Navidea Biopharmaceuticals to Present at the 2018 BIO Investor Forum

    Navidea Biopharmaceuticals, Inc. , a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today that its Chief Executive Officer, Jed Latkin, will present a corporate overview of the Company at the 2018 BIO Investor Forum, being held October 17-18, 2018 in San Francisco, California.

  • Benzinga5 months ago

    The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

    The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) Champions Oncology Inc (NASDAQ: CSBR ) Emergent Biosolutions ...

  • Business Wire5 months ago

    Navidea Biopharmaceuticals Announces Acceptance into the National Institutes of Health Commercialization Accelerator Program

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today acceptance into the National Institutes of Health (“NIH”) Commercialization Accelerator Program (“CAP”) 2018-2019. Frederick Cope, PI) entitled 99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (“RA”)-Driving Macrophages.

  • Business Wire5 months ago

    Navidea Biopharmaceuticals Announces Closing of a $3 Million Private Placement

    Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today closing of a $3 million private placement. The Company entered into a definitive securities purchase agreement with an existing investor, John K. Scott, Jr., pursuant to which the Company received aggregate gross proceeds of $3 million in exchange for the issuance of 18,320,610 shares of the Company’s common stock, par value $0.001 per share. The securities to be issued to Mr. Scott will represent approximately 10% of the Company’s outstanding common stock after such issuance.

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of NAVB earnings conference call or presentation 16-Aug-18 9:00pm GMT

    Q2 2018 Navidea Biopharmaceuticals Inc Earnings Call

  • ACCESSWIRE6 months ago

    Navidea Biopharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 16, 2018 / Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 16, 2018 at 5:00 ...

  • What Does Navidea Biopharmaceuticals Inc’s (NYSEMKT:NAVB) Ownership Structure Look Like?
    Simply Wall St.6 months ago

    What Does Navidea Biopharmaceuticals Inc’s (NYSEMKT:NAVB) Ownership Structure Look Like?

    In this analysis, my focus will be on developing a perspective on Navidea Biopharmaceuticals Inc’s (NYSEMKT:NAVB) latest ownership structure, a less discussed, but important factor. The impact of a company’sRead More...

  • Business Wire6 months ago

    Navidea Biopharmaceuticals Announces Details of 2018 Annual General Meeting

    As previously announced, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, will host a conference call today, August 16, 2018, at 5:00pm EDT to discuss details of the Annual Meeting for its shareholders, to be held today in Fort Lee, New Jersey under the chairmanship of Michael Rice, director of Navidea.

  • Business Wire6 months ago

    Navidea Biopharmaceuticals Receives Noncompliance Notice From NYSE American

    On August 14, 2018, Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, received a letter from NYSE American LLC (“NYSE American” or the “Exchange”) stating that it is not in compliance with the continued listing standards as set forth in Sections 1003(a)(ii) and 1003(f)(v) of the NYSE American Company Guide (the “Company Guide”). In order to maintain its listing, the Company must submit a plan of compliance by September 14, 2018 addressing how it intends to regain compliance with Section 1003(a)(ii) of the Company Guide by February 14, 2020.